Profile data is unavailable for this security.
About the company
Mangalam Drugs and Organics Limited is an India-based manufacturer of active pharmaceutical ingredients (APIs) and intermediates. Under the Company's Fight Malaria Program, it supplies anti-malaria APIs worldwide. Its products include API, intermediates and specialty chemicals. Its API products include acyclovir, amodiaquine, artemether, artesunate, atazanavir sulfate, bisoprolol fumarate, chloroquine phosphate, furosemide and dolutegravir sodium. The Company's intermediates products include 4,6-Dichloro-5-Methoxy Pyrimidine; 4,7- dichloroquinoline; ortho phenoxy methane sulfonanilide; tenofovir alafenamide base, and tenofovir disoproxil base. Its specialty chemical products include L (+)-menthol; 2,3-dihydrophthalazine-1,4-dione or phthalazine-1,4-dione, and 4-cynoethyl-2-methyl phenol. Its pipeline APIs (under development) include Ganaplacide (IH), Tafenoquine Succinate (IH) and Pretomanid (IH). Its pipeline APIs (developed for research and development) is Bictegravir Na (IH).
- Revenue in INR (TTM)2.38bn
- Net income in INR-309.21m
- Incorporated1972
- Employees414.00
- LocationMangalam Drugs and Organics Ltd3Rd FloorRupam Building 239, P. D'mello RoadMUMBAI 400001IndiaIND
- Phone+91 2 222616200
- Fax+91 2 222619090
- Websitehttps://www.mangalamdrugs.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JFL Life Sciences Ltd | 800.66m | 47.93m | 395.94m | 39.00 | 8.21 | -- | 6.62 | 0.4945 | 1.46 | 1.46 | 24.37 | -- | -- | -- | -- | -- | -- | 5.83 | -- | 10.64 | 22.23 | 18.28 | 6.02 | 5.73 | -- | 5.95 | -- | -- | 76.25 | 22.15 | 25.72 | 63.09 | -32.30 | -- |
| Jupiter Bioscience Ltd | -100.00bn | -100.00bn | 399.65m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.42 | -- | 5.61 | -- | 61.37 | -- | 17.32 | -- | -- | -- | 10.48 | 42.43 | 29.30 | 20.92 | 22.82 | 55.40 | -16.74 |
| Vilin Bio Med Ltd | 199.81m | 2.51m | 431.06m | -- | 171.30 | 1.86 | 121.32 | 2.16 | 0.1804 | 0.1804 | 14.34 | 16.64 | 0.6845 | 3.65 | 3.25 | -- | 0.8592 | 1.81 | 1.08 | 2.70 | 6.60 | 21.72 | 1.26 | 2.71 | 4.16 | 1.19 | 0.0193 | -- | -6.30 | -2.51 | 37.62 | 6.62 | 130.50 | -- |
| Lasa Supergenerics Ltd | 952.91m | -361.68m | 450.41m | 66.00 | -- | 0.7994 | -- | 0.4727 | -7.57 | -7.57 | 19.58 | 11.25 | 0.8705 | 6.06 | 36.08 | 14,437,960.00 | -33.04 | -6.42 | -46.76 | -8.54 | 22.28 | 28.58 | -37.96 | -8.05 | 0.5203 | -14.70 | 0.1152 | -- | 36.53 | -3.16 | 32.09 | -- | -- | -- |
| Mangalam Drugs and Organics Ltd | 2.38bn | -309.21m | 547.18m | 414.00 | -- | -- | -- | 0.2295 | -19.53 | -19.53 | 150.57 | -- | -- | -- | -- | 5,758,911.00 | -- | 2.90 | -- | 5.34 | 39.15 | 29.02 | -12.97 | 2.46 | -- | -0.9827 | -- | -- | -13.66 | 2.42 | 174.27 | -4.02 | 23.85 | -- |
| Vivimed Labs Ltd | 1.04bn | -243.69m | 563.81m | 586.00 | -- | -- | -- | 0.5415 | -2.93 | -2.93 | 12.54 | -5.78 | 0.1115 | 0.8832 | 1.17 | 1,776,860.00 | -2.60 | -9.00 | -4.80 | -13.91 | 51.93 | 27.65 | -23.29 | -35.17 | 0.6624 | -5.54 | 1.14 | -- | -22.00 | -35.71 | 29.67 | -- | -47.43 | -- |
| Vineet Laboratories Ltd | 570.37m | -166.97m | 585.02m | -- | -- | 2.34 | -- | 1.03 | -15.30 | -15.30 | 52.08 | 13.02 | 0.5785 | 1.01 | 4.23 | -- | -16.94 | -1.82 | -54.66 | -5.75 | 4.86 | 19.76 | -29.27 | -1.09 | 0.1186 | -3.06 | 0.7505 | -- | -50.20 | -- | -2,065.83 | -- | -- | -- |
| Biofil Chemicals and Pharmaceuticals Ltd | 425.20m | 28.59m | 616.13m | 26.00 | 21.60 | 2.89 | 19.42 | 1.45 | 1.75 | 1.75 | 25.87 | 13.09 | 0.8731 | 7.84 | 1.28 | 16,353,690.00 | 5.87 | 2.13 | 14.16 | 4.33 | 5.22 | 8.63 | 6.72 | 2.33 | 1.33 | 8.28 | 0.0009 | -- | -16.57 | 2.38 | -21.36 | -14.31 | -13.50 | -- |
| Onyx Biotec Ltd | 663.87m | 10.68m | 643.69m | -- | 30.50 | 1.18 | 15.54 | 0.9696 | 1.16 | 1.16 | 44.50 | 30.18 | 0.7814 | 3.90 | 2.95 | -- | 1.26 | -- | 1.90 | -- | 29.72 | -- | 1.61 | -- | 1.35 | 2.13 | 0.2233 | -- | 15.26 | -- | 36.31 | -- | -- | -- |
